Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 16/20 | 0.65 |
| ▸ | NR3C2 | P08235 | 16/20 | 0.65 |
| ▸ | PGR | P06401 | 12/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3227235 | 0.82 | NR3C1 (0.56) | NR3C1NR3C2PGRL3MBTL1MEN1 | |
| SCHEMBL3226421 | 0.79 | NR3C1 (1.00) | NR3C1NR3C2PGRL3MBTL1MEN1 | |
| SCHEMBL3227073 | 0.77 | NR3C1 (0.57) | NR3C1NR3C2PGRL3MBTL1 | |
| SCHEMBL4514428 | 0.77 | L3MBTL1 (0.83) | NR3C1L3MBTL1TDP1MEN1KMT2A | |
| SCHEMBL3222002 | 0.76 | NR3C1 (0.69) | NR3C1NR3C2PGRL3MBTL1MEN1 | |
| SCHEMBL3222276 | 0.76 | NR3C1 (0.61) | NR3C1NR3C2PGRMEN1KMT2A | |
| SCHEMBL3213636 | 0.75 | NR3C1 (0.76) | NR3C1NR3C2PGRMEN1KMT2A | |
| SCHEMBL21814326 | 0.75 | NR3C1 (0.58) | NR3C1NR3C2PGRL3MBTL1TDP1 | |
| SCHEMBL3213371 | 0.75 | NR3C1 (0.86) | NR3C1NR3C2PGRL3MBTL1 | |
| SCHEMBL3219845 | 0.75 | NR3C1 (0.58) | NR3C1NR3C2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048950-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-25 | — | — | US | claimed |
| EP-2136811-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2009-12-30 | — | — | EP | claimed |
| WO-2008124745-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-16 | — | — | WO | claimed |
| US-20100048950-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048950-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | NR3C1, MC2R, NR3C2 | NR3C1 1/4885NR3C2 3/4885PGR 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.